Therapy News and Research

RSS

GAPPS research into causes of preterm births and development of solutions

Thirteen million babies are born prematurely every year, but new funding announced today will allow for pioneering research into the causes of preterm births and the development of solutions so they can be prevented.

8 Nov 2011

Commitment of USAID promises future R&D breakthroughs in global health

Since USAID launched 50 years ago, the agency "has had a rich history of supporting global health, including research and development (R&D)," Global Health Technologies Coalition (GHTC) Director Kaitlin Christenson writes in the organization's "Breakthroughs" blog.

8 Nov 2011

Top-line results from AstraZeneca and Targacept's TC-5214 Phase 3 studies on MDD

AstraZeneca and Targacept, Inc. today announced top-line results from the first of four RENAISSANCE Phase 3 studies investigating the efficacy and tolerability of TC-5214 as an adjunct therapy to an antidepressant in patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant treatment.

8 Nov 2011

New technology can detect toxins in a person's breath

Breathing. Anyone reading this article is doing it right now. But what chemicals are we breathing in, and out? A group of Virginia Tech College of Engineering researchers has published a paper in the journal Environmental Science & Technology that details how to learn just that, using microelectromechanical systems to focus on toxins and everyday impurities that enter the body through the air we intake.

8 Nov 2011

States trying to wrangle Medicaid costs; rural hospitals struggling; health hiring steady

In Michigan, the plan to replace state nursing assistants at the veterans home resulted in a lawsuit contending that some temporary workers employed by the contract company had already jeopardized patient care. ... A judge has granted a preliminary injunction that keeps the state employees at work while the lawsuit moves forward.

8 Nov 2011

High-field MRI can reveal tiny brain injuries in preterm infant

Pediatric neuroscientists at Oregon Health & Science University Doernbecher Children's Hospital are the first to use high magnetic field strength MRI to reveal tiny white matter injuries in the developing brain previously undetectable using standard MRI.

8 Nov 2011

EpiCept reports net loss of $5.4 million for third quarter 2011

EpiCept Corporation today announced operating and financial results for the three and nine months ended September 30, 2011, and provided an update with respect to the Company's key business initiatives.

8 Nov 2011

Bristol-Myers Squibb receives FDA approval for Erbitux to treat head and neck cancer

The U.S. Food and Drug Administration today approved Erbitux (cetuximab) for use with chemotherapy to treat patients with late-stage (metastatic) head and neck cancer.

8 Nov 2011

First-ever Mantle Cell Lymphoma Symposium to be held on Nov. 12

The Lymphoma Division of the John Theurer Cancer Center at Hackensack University Medical Center with the participation from the Facebook groups "Hope for Lymphoma" and "Our MCL Family," will host its first-ever Mantle Cell Lymphoma Symposium on Saturday, November 12 from 8:30am - 3:45pm.

8 Nov 2011

DSM and Svelte Medical Systems enter into license and supply agreement

DSM, and Svelte® Medical Systems, Inc., a privately held company developing next generation endovascular therapies, today announced they have entered into a license and supply agreement granting Svelte the right to use DSM’s proprietary bioerodible amino acid based drug carrier in the design of their All In One non-thrombogenic, non-inflammatory drug-eluting stent system.

7 Nov 2011

AMS pleased with CMS' increase in 2012 payment rate for proton therapy

AMERICAN SHARED HOSPITAL SERVICES, a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, said today that the recent announcement by the Centers for Medicare & Medicade Services (CMS) of a 15% increase in the payment rate of proton therapy for hospital based centers beginning in 2012 strengthens the economic case for the proton centers now under development by the Company.

7 Nov 2011

Gilead, CRF commence ranolazine Phase 3 clinical trial for chronic stable angina in post-PCI setting

Gilead Sciences, Inc. and the Cardiovascular Research Foundation (CRF) today announced the initiation of RIVER-PCI (Ranolazine for Incomplete VEssel Revascularization post-PCI), a Phase 3 clinical trial evaluating the utility of ranolazine to prevent major adverse cardiovascular events (MACE) in patients with a history of chronic angina who have incomplete revascularization following percutaneous coronary intervention (PCI).

7 Nov 2011

Pharmacyclics first quarter GAAP net loss increases to $14.5M

Pharmacyclics, Inc. today reported financial results and recent developments for its fiscal first quarter ended September 30, 2011.

7 Nov 2011

American Access Care sold to to Fresenius Medical Care

TA Associates, a leading global growth private equity firm, today announced the sale of its portfolio company American Access Care (AAC) to Fresenius Medical Care AG & Co. KGaA.

7 Nov 2011

InfraReDx TVC Imaging System to be exhibited at TCT 2011

InfraReDx, Inc., a medical device company committed to advancing the diagnosis and management of coronary artery and other vascular diseases, today announced that its TVC Imaging System for the true vessel characterization of coronary artery disease will be highlighted during the annual Transcatheter Cardiovascular Therapeutics Meeting (TCT 2011).

7 Nov 2011

DuoCort Pharma granted marketing authorization for adrenal insufficiency drug, Plenadren in Europe

The Swedish specialty pharma company, DuoCort Pharma, announced today that the European Commission has granted a European Marketing Authorisation for Plenadren (hydrocortisone, modified release tablet), an orphan drug for treatment of adrenal insufficiency in adults, bringing these patients their first pharmaceutical innovation in over 50 years.

7 Nov 2011

ISET 2012 to discuss latest advances in chronic cerebrospinal venous insufficiency

Innovators in the field of endovascular therapy will explore the often-contentious topic of chronic cerebrospinal venous insufficiency (CCSVI), which is theorized to be a contributing factor in the development of multiple sclerosis (MS), at the 24th annual International Symposium on Endovascular Therapy.

7 Nov 2011

Positive top-line results from NPSP558 Phase 3 study on hypoparathyroidism

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing orphan therapeutics for rare gastrointestinal and endocrine disorders, today announced positive top-line results from REPLACE, a Phase 3 registration study of NPSP558, the company's bioengineered replica of human parathyroid hormone (rhPTH 1-84), in adult hypoparathyroidism patients.

7 Nov 2011

Karolinska Institute researchers discover novel cancer drug target

Vivolux AB, a drug discovery company specialized in cancer treatment, announced today that data that forms the basis for one of the company's promising projects has been published in the journal Nature Medicine. Researchers at the Karolinska Institute have discovered a novel cancer drug target.

7 Nov 2011

Tibotec to present results of TMC435 phase 2b study on HCV at AASLD 2011

Tibotec Pharmaceuticals (Tibotec), one of the Janssen (Janssen) Pharmaceutical Companies, today will present results of the final analysis of PILLAR, a phase 2b study of the investigational hepatitis C virus (HCV) NS3/4A protease inhibitor TMC435 in treatment-naïve patients with chronic genotype 1 HCV, as part of a late-breaker oral presentation at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco, CA, USA.

7 Nov 2011